Amixin® [Tilorone]

Pharmacological properties

Amixin ic (Tilorone) - an immunomodulating and antiviral agent. stimulates the formation of α-, β-, γ-interferons in the body. the main producers of interferon in response to the introduction of amixin ic are intestinal epithelial cells, hepatocytes, t-lymphocytes, neutrophils and granulocytes. after ingestion, the maximum production of interferon is determined in the sequence intestine - liver - blood after 4-24 hours. It stimulates bone marrow stem cells, depending on the dose it enhances antibody formation, reduces the degree of immunosuppression, and restores the ratio of t-suppressors / t-helpers. effective against a wide range of viral infections, including against influenza viruses, other acute respiratory viral infections, hepatitis a, b, c, herpes viruses. the mechanism of antiviral action is associated with inhibition of the translation of virus-specific proteins in infected cells, as a result of which reproduction of viruses is inhibited.

When conducting animal studies (chicken and duck embryos), the antiviral activity of the drug against the pathogen of highly pathogenic avian influenza (HPAI) strain H5N1 was proved, as well as (when conducting experiments on chickens) significant immunostimulating and adjuvant activity against antigens of the pathogen HPAI.

Pharmacokinetics After oral administration, Tilorone is rapidly absorbed in the digestive tract. Bioavailability is 60%. About 80% of the drug binds to plasma proteins. The drug does not undergo biotransformation and does not accumulate in the body. It is excreted almost unchanged with feces and urine in a ratio of 7: 1. T_½ is 48 hours

Indications

Adults: treatment of viral hepatitis a, b, c, herpetic infection, cytomegalovirus infection, as part of the complex treatment of infectious-allergic and viral encephalomyelitis (multiple sclerosis, leukoencephalitis, uveencephalitis and meningoencephalitis), urogenital and respiratory chlamydia; treatment and prevention of influenza and other acute respiratory viral infections. to reduce the degree of immunosuppression in the complex therapy of diseases accompanied by secondary induced immunodeficiency (caused by the influence of x-rays, cytostatics, surgical interventions, etc.) and requiring immunocorrection.

Children over the age of 7 years: for the treatment of influenza and other acute respiratory viral infections.

Application

The drug is taken orally after a meal.

Adults

Prevention of viral hepatitis A - 125 mg / week for 6 weeks.

Treatment of viral hepatitis A - on the first day, 125 mg 2 times a day, after which - 125 mg with an interval of 48 hours. Course dose - 1.25 g.

Treatment of acute hepatitis B - in the first 2 days, 125 mg, after which - 125 mg with an interval of 48 hours. Course dose - 2 g. With a prolonged course of hepatitis B, the course dose can be increased to 2.5 g.

In chronic hepatitis B - 250 mg is taken in the first 2 days, after which - 125 mg with an interval of 48 hours. The course dose at the beginning of treatment is 2.5 g. Subsequently, the drug is taken at a dose of 125 mg / week. The total course dose is from 3.75 to 5 g.

In acute hepatitis C - in the first 2 days of treatment - 125 mg, after which - 125 mg with an interval of 48 hours. Course dose - 2.5 g.

In chronic hepatitis C - in the first 2 days of treatment - 250 mg, after which - 125 mg with an interval of 48 hours. The course dose at the beginning of treatment is 2.5 g. Subsequently, the drug is taken at a dose of 125 mg / week. The total course dose is 5 g.

In the treatment of influenza and other acute respiratory viral infections - 125 mg in the first 2 days of treatment, after which - 125 mg with an interval of 48 hours. The total course dose is 750 mg.

For the prevention of influenza and other acute respiratory viral infections, take 125 mg once a week for 6 weeks.

For the treatment of herpetic, cytomegalovirus infection - 125 mg is taken in the first 2 days, then 125 mg with an interval of 48 hours. The total course dose is 2.5 g.

To reduce the degree of immunosuppression as part of the complex therapy of diseases accompanied by secondary induced immunodeficiency and requiring immunocorrection, 125–250 mg / week for 6 weeks. The maximum course dose is 1.5 g. Depending on the immunological parameters and the course of the disease, the course of treatment can be repeated with an interval between courses of 4 weeks.

With urogenital and respiratory chlamydia, take 125 mg in the first 2 days, after which - 125 mg with an interval of 48 hours. Course dose - 1.25 g.

As part of the complex treatment of neuroviral infections - infectious-allergic and viral encephalomyelitis (multiple sclerosis, leukoencephalitis, uveoencephalitis and meningoencephalitis) - 125 mg in the first 2 days, then 125 mg each with an interval of 48 hours. Course dose - from 1.5 up to 1.75 g.

Children over the age of 7 years with uncomplicated forms of influenza or other acute respiratory viral infections take 60 mg once a day on the 1st, 2nd and 4th day from the start of treatment. The course dose is 180 mg. If complications of influenza or other acute respiratory viral infections occur, the drug is taken at 60 mg / day on the 1st, 2nd, 4th and 6th day from the start of treatment. The course dose is 240 mg.

Contraindications

Increased individual sensitivity to the components of the drug.

Side effects

On the part of the skin and subcutaneous tissue: allergic reactions, including pruritus, rash (in particular, urticaria).

From the digestive tract: dyspeptic symptoms (in particular, nausea, heartburn).

Others: short-term fever.

special instructions

During pregnancy and breastfeeding. there is no experience with the use of the drug during pregnancy and lactation, therefore, the drug should not be prescribed in this period.

Children. Do not use in children under 7 years of age.

Influence on the ability to drive vehicles and work with other mechanisms. Does not affect.

Interactions

Compatible with antibiotics and traditional bacterial and viral diseases.

Overdose

Cases of an overdose of amixin ic are unknown.

Storage conditions

In the original packaging at a temperature not exceeding 25 ° C.